• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

内镜息肉切除术(EPIC)与内镜鼻窦手术治疗伴有息肉的慢性鼻-鼻窦炎的病例对照研究。

Case-control study of endoscopic polypectomy in clinic (EPIC) versus endoscopic sinus surgery for chronic rhinosinusitis with polyps.

机构信息

Department of Otolaryngology - Head and Neck Surgery, The University of Ottawa, Ottawa, Canada.

The Ottawa Hospital Research Institute (OHRI), Ottawa, Canada.

出版信息

Rhinology. 2018 Jun 1;56(2):155-157. doi: 10.4193/Rhin17.115.

DOI:10.4193/Rhin17.115
PMID:29306958
Abstract

INTRODUCTION

Endoscopic Polypectomy In Clinic (EPIC) is a recently described deescalated form of endoscopic sinus surgery (ESS) performed in the outpatient clinic for patients with chronic rhinosinusitis with polyps (CRSwNP). The quality of life benefit of EPIC in comparison to ESS is not known. The purpose of this study was to determine if the disease specific quality of life measured with the SNOT-22 attained with EPIC is similar to that attained with ESS for patients with CRSwNP.

METHODS

A multi-institutional observational case-control study was performed to evaluate quality of life improvement in patients treated with ESS and EPIC for CRSwNP with a 3 month follow-up. Predicted probability of undergoing EPIC was calculated by fitting a logistic regression model using clinically relevant variables. EPIC patients were matched to ESS patients in a 1:1 fashion.

RESULTS

24 pairs were analyzed after matching. There was no statistical difference in the post-treatment SNOT-22 scores or proportion of patients achieving a minimal clinically important difference.

CONCLUSIONS

In appropriate CRSwNP patients, the EPIC procedure may provide disease specific quality of life improvement similar to that seen with patients who undergo traditional ESS.

摘要

简介

内镜下息肉切除术(EPIC)是一种最近描述的内镜鼻窦手术(ESS)降级形式,在门诊为慢性鼻-鼻窦炎伴息肉(CRSwNP)患者进行。EPIC 与 ESS 相比的生活质量获益尚不清楚。本研究旨在确定使用 SNOT-22 测量的 EPIC 治疗 CRSwNP 患者的疾病特异性生活质量是否与 ESS 治疗的患者相似。

方法

进行了一项多机构观察性病例对照研究,以评估 ESS 和 EPIC 治疗 CRSwNP 患者的 3 个月随访时的生活质量改善情况。使用临床相关变量拟合逻辑回归模型来计算接受 EPIC 的预测概率。以 1:1 的比例将 EPIC 患者与 ESS 患者相匹配。

结果

匹配后分析了 24 对。治疗后 SNOT-22 评分或达到最小临床重要差异的患者比例没有统计学差异。

结论

在适当的 CRSwNP 患者中,EPIC 手术可能会提供与接受传统 ESS 治疗的患者相似的疾病特异性生活质量改善。

相似文献

1
Case-control study of endoscopic polypectomy in clinic (EPIC) versus endoscopic sinus surgery for chronic rhinosinusitis with polyps.内镜息肉切除术(EPIC)与内镜鼻窦手术治疗伴有息肉的慢性鼻-鼻窦炎的病例对照研究。
Rhinology. 2018 Jun 1;56(2):155-157. doi: 10.4193/Rhin17.115.
2
Comparison of the surgical outcome between primary and revision endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis.伴有鼻息肉的慢性鼻窦炎初次与翻修鼻内镜鼻窦手术的手术效果比较。
Am J Otolaryngol. 2008 Nov-Dec;29(6):379-84. doi: 10.1016/j.amjoto.2007.11.005. Epub 2008 Jun 13.
3
Systematic Review and Meta-analysis of SNOT-22 Outcomes after Surgery for Chronic Rhinosinusitis with Nasal Polyposis.慢性鼻-鼻窦炎伴鼻息肉患者行手术治疗后的 SNOT-22 结局的系统评价和荟萃分析。
Otolaryngol Head Neck Surg. 2018 Sep;159(3):414-423. doi: 10.1177/0194599818773065. Epub 2018 May 1.
4
Gender-specific differences in chronic rhinosinusitis patients electing endoscopic sinus surgery.慢性鼻-鼻窦炎患者行内镜鼻窦手术的性别差异。
Int Forum Allergy Rhinol. 2016 Mar;6(3):278-86. doi: 10.1002/alr.21667. Epub 2015 Nov 17.
5
Endoscopic polypectomy performed in clinic for chronic rhinosinusitis with nasal polyps: study protocol for the EPIC multicentre randomised controlled trial.临床内镜下息肉切除术治疗慢性鼻窦炎伴鼻息肉:EPIC多中心随机对照试验的研究方案
BMJ Open. 2020 Dec 2;10(12):e042413. doi: 10.1136/bmjopen-2020-042413.
6
Efficacy of buffered hypertonic seawater in different phenotypes of chronic rhinosinusitis with nasal polyps after endoscopic sinus surgery: a randomized double-blind study.缓冲高渗海水对内镜鼻窦手术后不同表型慢性鼻-鼻窦炎伴鼻息肉患者的疗效:一项随机双盲研究。
Am J Otolaryngol. 2020 Sep-Oct;41(5):102554. doi: 10.1016/j.amjoto.2020.102554. Epub 2020 May 26.
7
Efficacy of ESS in chronic rhinosinusitis with and without nasal polyposis: a Danish cohort study.ESS治疗伴或不伴鼻息肉的慢性鼻窦炎的疗效:一项丹麦队列研究。
Eur Arch Otorhinolaryngol. 2016 Apr;273(4):911-9. doi: 10.1007/s00405-015-3667-9. Epub 2015 Jun 2.
8
Cost Utility Analysis of Dupilumab Versus Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps.度普利尤单抗与内镜鼻窦手术治疗鼻息肉慢性鼻-鼻窦炎的成本效用分析。
Laryngoscope. 2021 Jan;131(1):E26-E33. doi: 10.1002/lary.28648. Epub 2020 Apr 3.
9
Pre-treatment SNOT-22 score predicts response to Endoscopic Polypectomy in Clinic (EPIC) our experience in 30 adults.治疗前SNOT-22评分可预测临床内镜下息肉切除术(EPIC)的疗效:我们对30例成人患者的经验
Clin Otolaryngol. 2017 Jun;42(3):732-734. doi: 10.1111/coa.12623. Epub 2016 Feb 9.
10
Endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps: Clinical outcome and predictive factors of recurrence.鼻内镜鼻窦手术治疗慢性鼻窦炎伴鼻息肉:临床疗效及复发的预测因素
Am J Rhinol Allergy. 2017 Jan 1;31(1):56-62. doi: 10.2500/ajra.2017.31.4402.

引用本文的文献

1
[Not Available].[无可用内容]。
Allergo J. 2022;31(6):24-39. doi: 10.1007/s15007-022-5080-1. Epub 2022 Sep 5.
2
[Dupilumab has an additional benefit in treatment of chronic rhinosinusitis with nasal polyps].度普利尤单抗在治疗伴有鼻息肉的慢性鼻-鼻窦炎方面具有额外益处。
HNO. 2021 Nov;69(11):868-877. doi: 10.1007/s00106-021-01018-z. Epub 2021 Mar 18.
3
Endoscopic polypectomy performed in clinic for chronic rhinosinusitis with nasal polyps: study protocol for the EPIC multicentre randomised controlled trial.临床内镜下息肉切除术治疗慢性鼻窦炎伴鼻息肉:EPIC多中心随机对照试验的研究方案
BMJ Open. 2020 Dec 2;10(12):e042413. doi: 10.1136/bmjopen-2020-042413.
4
In-office endoscopic nasal polypectomy: prospective analysis of patient tolerability and efficacy.门诊鼻内镜下鼻息肉切除术:患者耐受性和疗效的前瞻性分析。
Eur Arch Otorhinolaryngol. 2020 Dec;277(12):3341-3348. doi: 10.1007/s00405-020-06196-0. Epub 2020 Jul 14.
5
[Not Available].[无可用内容]
Laryngorhinootologie. 2020 Jun;99(6):356-364. doi: 10.1055/a-1164-9696. Epub 2020 May 8.
6
EUFOREA consensus on biologics for CRSwNP with or without asthma.EUFOREA 共识:针对伴有或不伴哮喘的 CRSwNP 使用生物制剂。
Allergy. 2019 Dec;74(12):2312-2319. doi: 10.1111/all.13875. Epub 2019 Jul 15.